Non-‘classical’ MEKs: A review of MEK3-7 inhibitors

Ada J. Kwong, Karl A. Scheidt*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The MAPK pathways are an enduring area of interest due to their essential roles in cell processes. Increased expression and activity can lead to a multitude of diseases, sparking research efforts in developing inhibitors against these kinases. Though great strides have been made in developing MEK1/2 inhibitors, there is a notable lack of chemical probes for MEK3-7, given their central role in stimuli response, cell growth, and development. This review summarizes the progress that has been made on developing small molecule probes for MEK3-7, the specific disease states in which they have been studied, and their potential to become novel therapeutics.

Original languageEnglish (US)
Article number127203
JournalBioorganic and Medicinal Chemistry Letters
Issue number13
StatePublished - Jul 1 2020


  • Drug discovery
  • Kinases
  • Mitogen-activated protein kinases
  • Small molecule inhibitors
  • Structure-activity relationships

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Molecular Biology
  • Biochemistry
  • Clinical Biochemistry
  • Pharmaceutical Science
  • Organic Chemistry


Dive into the research topics of 'Non-‘classical’ MEKs: A review of MEK3-7 inhibitors'. Together they form a unique fingerprint.

Cite this